Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021

Rhea-AI Summary

Kiniksa Pharmaceuticals (KNSA) will host a conference call on November 1, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and recent developments. Interested parties can access the live webcast through the company's website, with a replay available within 48 hours. Kiniksa focuses on developing therapeutic medicines for debilitating diseases with unmet needs, featuring assets like ARCALYST, mavrilimumab, vixarelimab, and KPL-404. These therapies target immunological pathways and aim to differentiate within their respective markets.

Positive

• Focus on developing therapeutic medicines for significant unmet medical needs.
• Portfolio includes differentiated assets targeting underserved conditions.

Negative

• None.

HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8:30 a.m. Eastern Time to report its third quarter 2021 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1699563.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST^® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com

FAQ

What is Kiniksa Pharmaceuticals' upcoming conference call about?

Kiniksa Pharmaceuticals' conference call on November 1, 2021, will cover their Q3 2021 financial results and recent portfolio execution.

How can I access Kiniksa Pharmaceuticals' conference call?

You can access the conference call by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1699563.

What are the main therapeutic assets of Kiniksa Pharmaceuticals?

Kiniksa's main therapeutic assets include ARCALYST, mavrilimumab, vixarelimab, and KPL-404, aimed at modulating immunological pathways.

When will the replay of the Kiniksa conference call be available?

The replay of the Kiniksa conference call will be available approximately 48 hours after the live event.